The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; National Bioproducts Institute; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca Japan; Bristol-Myers Squibb Japan; Ono Pharmaceutical
Research Funding - AstraZeneca; Bristol-Myers Squibb Japan; Ono Pharmaceutical
Voltage: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer.
 
Takayuki Yoshino
Research Funding - Chugai Pharma (Inst); GlaxoSmithKline (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst)
 
Hideaki Bando
Research Funding - AstraZeneca; Sysmex
 
Yuichiro Tsukada
No Relationships to Disclose
 
Koji Inamori
No Relationships to Disclose
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yoshito Komatsu
Honoraria - Bayer; Novartis; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Nipro Corporation; Novartis; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda; TOWA; Yakult Honsha
Research Funding - Astellas Pharma; Bayer; Boehringer Ingelheim; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly; MSD; Novartis; Ono Pharmaceutical; Sanofi; Sysmex; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
 
Shigenori Homma
No Relationships to Disclose
 
Mamoru Uemura
No Relationships to Disclose
 
Takeshi Kato
Honoraria - Bayer; Chugai Pharma; Lilly; Sanofi; Takeda; Yakult Honsha
Research Funding - Chugai Pharma
 
Daisuke Kotani
No Relationships to Disclose
 
Shota Fukuoka
Research Funding - Bayer (Inst); MSD (Inst); Ono Pharmaceutical (Inst)
 
Takeshi Sasaki
No Relationships to Disclose
 
Yuji Nishizawa
No Relationships to Disclose
 
Naoki Nakamura
No Relationships to Disclose
 
Masashi Wakabayashi
Honoraria - Chugai Pharma; Johnson & Johnson
 
Motohiro Kojima
No Relationships to Disclose
 
Yosuke Togashi
No Relationships to Disclose
 
Akihiro Sato
Honoraria - AstraZeneca; Dainippon Sumitomo Pharma
Research Funding - Aspyerian Therapeutics (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); MSD (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Hiroyoshi Nishikawa
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Ono Pharmaceutical
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Asahi Kasei; Astellas Pharma; AstraZeneca; BD Biosciences; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Zenyaku Kogyo
 
Masaaki Ito
No Relationships to Disclose